Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: A serological study within a randomised trial of different measles vaccines

Vaccine

Volumn 31, Issue 48, 2013, Pages 5766-5771

  Martins, Cesario ^a   Garly, May Lill ^a,b   Bale, Carlitos ^a   Rodrigues, Amabelia ^a   Benn, Christine S ^a,b   Whittle, Hilton ^c   Aaby, Peter ^a,b  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b STATENS SERUM INSTITUT   (Denmark)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Antibody response; Edmonston Zagreb measles vaccine; Non specific effects of vaccines; Schwarz measles vaccine; Two dose measles vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES ANTIBODY; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; SCHWARZ VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CHILD HOSPITALIZATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DIPHTHERIA; DISEASE SURVEILLANCE; DRUG INDICATION; EPIDEMIC; FEMALE; GEOMETRIC MEAN TITER; GUINEA-BISSAU; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MULTICENTER STUDY; NEWBORN; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SEROLOGY; SEX DIFFERENCE; TETANUS; URBAN AREA; VIRUS STRAIN;

ANTIBODY RESPONSE; EDMONSTON-ZAGREB MEASLES VACCINE; NON-SPECIFIC EFFECTS OF VACCINES; SCHWARZ MEASLES VACCINE; TWO-DOSE MEASLES VACCINATION;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; GUINEA-BISSAU; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEASLES; MEASLES VACCINE; VACCINATION;

EID: 84886952966     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.044     Document Type: Article

References (23)

1. Expanded Programme on Immunization Safety of high titre measles vaccines. Wkly Epidemiol Rec 1992, 67:357-361.
2. Rosenthal S.R., Clement C.J. Two-dose measles vaccination schedule. Bull World Health Organ 1993, 71:421-428.
3. Aaby P., Garly M.L., Balé C., Martins C., Jensen H., Lisse I.M., Whittle H. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: An unplanned study. PIDJ 2003, 22:798-805.
4. Garly M-L., Matins C.L., Balé C., da Costa F., Dias F., Whittle H.C., et al. Early two-dose measles vaccination schedule in Guinea-Bissau: Good protection and coverage in infancy. Int J Epidemiol 1999, 28:347-352.
5. Garly M-L., Balé C., Martins C.L., Monteiro M., George E., Kidd M., et al. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonoston-Zagreb and Schwartz standard titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 1919, 2001:51-59.
6. Aaby P., Garly M.L., Jensen H., Martins C., Balé C., Benn C.S., Rodrigues A., Lisse I.M. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: observations from vaccination trials in Guinea-Bissau. PIDJ 2007, 26:247-252.
7. Global measles mortality reduction and regional elimination, 2000-2002. Part I. Wkly Epidmiol Rec 2002; 77:50-5.
8. De Quadros C.A., Izurieta H., Venczel L., Carrasco P. Measles eradication in the Americas: progress to date. JID 2004, 189(Suppl 1):S227-S235.
9. Meeting of the immunization Strategic Advisory Group of Experts, November 2006-conclusions and recommendations. Wkly Epidmiol Rec 2007; 82:1-16.
10. Taylor W.R., KaLisa R., Ma-Disu M., Weinman J.M. Measles control in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol 1988, 127:788-794.
11. Martins C.L., Garly M.L., Balé C., Rodrigues A., Ravn H., Whittle H.C., Lisse I.M., Aaby P. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008, 337. a661; epub.
12. Aaby P., Samb B., Simondon F., Seck A.M.C., Knudsen K., Whittle H.C. Non-specific beneficial effect of measles immunization: analysis of mortality studies from developing countries. BMJ 1995, 311:481-485.
13. George K., Joseph A., Muliyil J., Abraham S., Bhattacharji S., Jonhn K.R. Measles vaccination before nine months. Trop Med Int Health 1998, 3:751-756.
14. Aaby P., Martins C.L., Garly M.L., Bale C., Andersen A., Rodrigues A., Ravn H., Lisse I.M., Benn C.S., Whittle H. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: Randomised controlled trial. BMJ 2010, 341. c6495.
15. Aaby P., Martins C.L., Garly M.L., Rodrigues A., Benn C.S., Whittle H.C. The optimal age of measles immunization in low-income countries: A secondary analysis of the assumptions underlying the current policy. BMJ Open 2012, 2:e000761.
16. Whittle H.C., Aaby P., Samb B., Cisse B., Kanteh F., Soumare M. Poor serological responses 5-7 years after immunization with high and standard titre measles vaccines. Pediatr Infect Dis J 1999, 149:295-301.
17. Norrby E. Hemagglutination by measles virus. Proc Soc Exp Biol Med 1962, 111:814-818.
18. Martins C., Carlitos Bale C., Garly M.L., Rodrigues A., Lisse I.M., Andersen A., Eriksson M., Benn C.S., Whittle H., Aaby P. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009, 27:5220-5225.
19. Martins C.L. Nìveis de anticorpos contra o sarampo entre as mulheres em idade fertile na populacão da Guinè-Bissau expostas a sarampo natural e a imunizacão contra sarampo. MSc Thesis 2002, Osvaldo Cruz, Brazil.
20. Whittle H.C., Campbell H., Rahman S., Armstrong J.R. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990, 336:1046-1048.
21. Benn C.S., Aaby P., Balé C., Michaelsen K.F., Olsen J., George E., Whittle H. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa. Lancet 1997, 350:101-105.
22. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with Coxsackievirus group B Type 3. J Virol 1994, 68:5126-5132.
23. Cisse B. Measles antibody levels among women of fertile age and decay of maternal antibodies in a West African population exposed to natural measles and measles immunisation. MSc Thesis 2001, London School of Hygiene and Tropical Medicine, London.